{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T04:04:17Z","timestamp":1745121857203,"version":"3.40.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03079-1","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T18:02:32Z","timestamp":1741629752000},"page":"467-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-6883","authenticated-orcid":false,"given":"Diego","family":"Velasco-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Mart\u00ednez-Alfonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Eterio","family":"Velasco-Valdazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Domingo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Revilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mah\u00edllo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Askari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Vidal Laso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fern\u00e1ndez-Cuezva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Castro-Quismondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Serrano-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mart\u00edn-Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Yuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"S\u00e1nchez-Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Jim\u00e9nez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyes","family":"de la Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Calvo-Villas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Llamas-Sillero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"Suppl 1","key":"3079_CR1","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","volume":"140","author":"FWG Leebeek","year":"2016","unstructured":"Leebeek FWG (2016) Update of thrombosis in multiple myeloma. Thromb Res 140(Suppl 1):S76-80. https:\/\/doi.org\/10.1016\/S0049-3848(16)30103-7","journal-title":"Thromb Res"},{"key":"3079_CR2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood.2020006648","volume":"136","author":"SM Rubinstein","year":"2020","unstructured":"Rubinstein SM, Tuchman SA (2020) Thrombosis in the modern era of multiple myeloma. Blood 136:1019\u20131021. https:\/\/doi.org\/10.1182\/blood.2020006648","journal-title":"Blood"},{"key":"3079_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046\u20131060. https:\/\/doi.org\/10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"3079_CR4","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","volume":"112","author":"SY Kristinsson","year":"2008","unstructured":"Kristinsson SY, Fears TR, Gridley G et al (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112:3582\u20133586. https:\/\/doi.org\/10.1182\/blood-2008-04-151076","journal-title":"Blood"},{"key":"3079_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0031-1273085","volume":"37","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Brioli A, Tacchetti P et al (2011) Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 37:209\u2013219. https:\/\/doi.org\/10.1055\/s-0031-1273085","journal-title":"Semin Thromb Hemost"},{"key":"3079_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1160\/TH10-03-0187","volume":"105","author":"JJA Auwerda","year":"2011","unstructured":"Auwerda JJA, Yuana Y, Osanto S et al (2011) Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 105:14\u201320. https:\/\/doi.org\/10.1160\/TH10-03-0187","journal-title":"Thromb Haemost"},{"key":"3079_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-2003-40965","volume":"29","author":"M Zangari","year":"2003","unstructured":"Zangari M, Saghafifar F, Mehta P et al (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29:275\u2013282. https:\/\/doi.org\/10.1055\/s-2003-40965","journal-title":"Semin Thromb Hemost"},{"key":"3079_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0022-2143(96)90116-x","volume":"128","author":"ME Carr","year":"1996","unstructured":"Carr ME, Dent RM, Carr SL (1996) Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 128:83\u201388. https:\/\/doi.org\/10.1016\/s0022-2143(96)90116-x","journal-title":"J Lab Clin Med"},{"key":"3079_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/(sici)1096-8652(199910)62:2<99::aid-ajh6>3.0.co;2-n","volume":"62","author":"Z Yasin","year":"1999","unstructured":"Yasin Z, Quick D, Thiagarajan P et al (1999) Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 62:99\u2013102. https:\/\/doi.org\/10.1002\/(sici)1096-8652(199910)62:2%3c99::aid-ajh6%3e3.0.co;2-n","journal-title":"Am J Hematol"},{"key":"3079_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","volume":"13","author":"M Zangari","year":"2002","unstructured":"Zangari M, Saghafifar F, Anaissie E et al (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13:187\u2013192. https:\/\/doi.org\/10.1097\/00001721-200204000-00003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3079_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","volume":"134","author":"F Elice","year":"2006","unstructured":"Elice F, Fink L, Tricot G et al (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134:399\u2013405. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06208.x","journal-title":"Br J Haematol"},{"key":"3079_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000071636","volume":"33","author":"HC Hemker","year":"2003","unstructured":"Hemker HC, Giesen P, Al Dieri R et al (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4\u201315. https:\/\/doi.org\/10.1159\/000071636","journal-title":"Pathophysiol Haemost Thromb"},{"key":"3079_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0135-y","volume":"8","author":"D Fotiou","year":"2018","unstructured":"Fotiou D, Sergentanis TN, Papageorgiou L et al (2018) Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J 8:1\u201313. https:\/\/doi.org\/10.1038\/s41408-018-0135-y","journal-title":"Blood Cancer J"},{"key":"3079_CR14","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3109\/10428194.2015.1041385","volume":"56","author":"MA Gracheva","year":"2015","unstructured":"Gracheva MA, Urnova ES, Sinauridze EI et al (2015) Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 56:3418\u20133425. https:\/\/doi.org\/10.3109\/10428194.2015.1041385","journal-title":"Leuk Lymphoma"},{"key":"3079_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2017.08.011","volume":"66","author":"P Legendre","year":"2017","unstructured":"Legendre P, Verstraete E, Martin M et al (2017) Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma. Blood Cells Mol Dis 66:47\u201349. https:\/\/doi.org\/10.1016\/j.bcmd.2017.08.011","journal-title":"Blood Cells Mol Dis"},{"key":"3079_CR16","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1080\/10428194.2019.1585839","volume":"60","author":"Y Dargaud","year":"2019","unstructured":"Dargaud Y, Fouassier M, Bordet JC et al (2019) The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis? Leuk Lymphoma 60:2572\u20132575. https:\/\/doi.org\/10.1080\/10428194.2019.1585839","journal-title":"Leuk Lymphoma"},{"key":"3079_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.thromres.2021.03.015","volume":"202","author":"T Nielsen","year":"2021","unstructured":"Nielsen T, Kristensen SR, Gregersen H et al (2021) Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Thromb Res 202:108\u2013118. https:\/\/doi.org\/10.1016\/j.thromres.2021.03.015","journal-title":"Thromb Res"},{"key":"3079_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.919495","volume":"9","author":"L Li","year":"2022","unstructured":"Li L, Roest M, Sang Y et al (2022) Patients with multiple myeloma have a disbalanced whole blood thrombin generation profile. Front Cardiovasc Med 9:919495. https:\/\/doi.org\/10.3389\/fcvm.2022.919495","journal-title":"Front Cardiovasc Med"},{"key":"3079_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.thromres.2007.05.016","volume":"121","author":"AD Petropoulou","year":"2008","unstructured":"Petropoulou AD, Gerotziafas GT, Samama MM et al (2008) In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res 121:493\u2013497. https:\/\/doi.org\/10.1016\/j.thromres.2007.05.016","journal-title":"Thromb Res"},{"key":"3079_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/MBC.0000000000000315","volume":"26","author":"A Undas","year":"2015","unstructured":"Undas A, Zubkiewicz-Usnarska L, Helbig G et al (2015) Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Blood Coagul Fibrinolysis 26:621\u2013627. https:\/\/doi.org\/10.1097\/MBC.0000000000000315","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3079_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1076029615625825","volume":"22","author":"MP Crowley","year":"2016","unstructured":"Crowley MP, Kevane B, O\u2019Shea SI et al (2016) Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance. Clin Appl Thromb Hemost 22:554\u2013562. https:\/\/doi.org\/10.1177\/1076029615625825","journal-title":"Clin Appl Thromb Hemost"},{"key":"3079_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","volume":"65","author":"M Leiba","year":"2017","unstructured":"Leiba M, Malkiel S, Budnik I et al (2017) Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis 65:1\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2017.03.010","journal-title":"Blood Cells Mol Dis"},{"key":"3079_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2016.1219900","volume":"58","author":"IS Tiong","year":"2017","unstructured":"Tiong IS, Rodgers SE, Lee CHS, McRae SJ (2017) Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma. Leuk Lymphoma 58:941\u2013949. https:\/\/doi.org\/10.1080\/10428194.2016.1219900","journal-title":"Leuk Lymphoma"},{"key":"3079_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/rth2.12161","volume":"3","author":"E Chalayer","year":"2018","unstructured":"Chalayer E, Tardy-Poncet B, Karlin L et al (2018) Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: an observational cohort study. Res Pract Thromb Haemost 3:89\u201398. https:\/\/doi.org\/10.1002\/rth2.12161","journal-title":"Res Pract Thromb Haemost"},{"key":"3079_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/ijlh.13093","volume":"41","author":"H Baccouche","year":"2019","unstructured":"Baccouche H, Hadhri M, Aissi W et al (2019) The hypercoagulable state in multiple myeloma: the contribution of thrombin generation test. Int J Lab Hematol 41:684\u2013690. https:\/\/doi.org\/10.1111\/ijlh.13093","journal-title":"Int J Lab Hematol"},{"key":"3079_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11239-022-02765-8","volume":"55","author":"D Velasco-Rodr\u00edguez","year":"2023","unstructured":"Velasco-Rodr\u00edguez D, Mart\u00ednez-Alfonzo I, Velasco-Valdazo AE et al (2023) Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma. J Thromb Thrombolysis 55:464\u2013473. https:\/\/doi.org\/10.1007\/s11239-022-02765-8","journal-title":"J Thromb Thrombolysis"},{"key":"3079_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cam4.1927","volume":"8","author":"HA Baker","year":"2019","unstructured":"Baker HA, Brown AR, Mahnken JD et al (2019) Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med 8:455\u2013462. https:\/\/doi.org\/10.1002\/cam4.1927","journal-title":"Cancer Med"},{"key":"3079_CR28","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"3079_CR29","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"3079_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/rth2.12238","volume":"3","author":"S Calzavarini","year":"2019","unstructured":"Calzavarini S, Brodard J, Quarroz C et al (2019) Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability. Res Pract Thromb Haemost 3:758\u2013768. https:\/\/doi.org\/10.1002\/rth2.12238","journal-title":"Res Pract Thromb Haemost"},{"key":"3079_CR31","unstructured":"R: a language and environment for statistical computing. https:\/\/www.gbif.org\/tool\/81287\/r-a-language-and-environment-for-statistical-computing. Accessed 10 Feb 2025"},{"key":"3079_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","volume":"32","author":"AMW van Marion","year":"2008","unstructured":"van Marion AMW, Auwerda JJA, Lisman T et al (2008) Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 32:1078\u20131084. https:\/\/doi.org\/10.1016\/j.leukres.2007.12.002","journal-title":"Leuk Res"},{"key":"3079_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.thromres.2014.04.010","volume":"134","author":"SE Rodgers","year":"2014","unstructured":"Rodgers SE, Wong A, Gopal RD et al (2014) Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thromb Res 134:160\u2013164. https:\/\/doi.org\/10.1016\/j.thromres.2014.04.010","journal-title":"Thromb Res"},{"key":"3079_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.thromres.2014.12.015","volume":"136","author":"J Perrin","year":"2015","unstructured":"Perrin J, Depasse F, Lecompte T et al (2015) Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res 136:125\u2013130. https:\/\/doi.org\/10.1016\/j.thromres.2014.12.015","journal-title":"Thromb Res"},{"key":"3079_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.thromres.2015.04.020","volume":"136","author":"CN Bagot","year":"2015","unstructured":"Bagot CN, Leishman E (2015) Establishing a reference range for thrombin generation using a standard plasma significantly improves assay precision. Thromb Res 136:139\u2013143. https:\/\/doi.org\/10.1016\/j.thromres.2015.04.020","journal-title":"Thromb Res"},{"key":"3079_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12185-020-02954-2","volume":"112","author":"J Wang","year":"2020","unstructured":"Wang J, Kim Y (2020) Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systematic review and meta-analysis. Int J Hematol 112:650\u2013657. https:\/\/doi.org\/10.1007\/s12185-020-02954-2","journal-title":"Int J Hematol"},{"key":"3079_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","volume":"6","author":"J van den Berg","year":"2022","unstructured":"van den Berg J, Kremer Hovinga JA, Pfleger C et al (2022) Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Adv 6:993\u2013997. https:\/\/doi.org\/10.1182\/bloodadvances.2021005124","journal-title":"Blood Adv"},{"key":"3079_CR38","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.7534\/j.issn.1009-2137.2016.05.002","volume":"24","author":"C-F Sun","year":"2016","unstructured":"Sun C-F, Zhao X, Han F et al (2016) Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24:1294\u20131298. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2016.05.002","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"3079_CR39","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/blood-2019-128238","volume":"134","author":"ER Fedyk","year":"2019","unstructured":"Fedyk ER, Idamakanti N, Chen J et al (2019) The binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells. Blood 134:3136. https:\/\/doi.org\/10.1182\/blood-2019-128238","journal-title":"Blood"},{"key":"3079_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","volume":"11","author":"M Zangari","year":"2011","unstructured":"Zangari M, Fink L, Zhan F, Tricot G (2011) Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 11:228\u2013236. https:\/\/doi.org\/10.1016\/j.clml.2011.03.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3079_CR41","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","volume":"100","author":"M Zangari","year":"2002","unstructured":"Zangari M, Siegel E, Barlogie B et al (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100:1168\u20131171. https:\/\/doi.org\/10.1182\/blood-2002-01-0335","journal-title":"Blood"},{"key":"3079_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"A Anagnostopoulos","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768\u2013771. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04345.x","journal-title":"Br J Haematol"},{"key":"3079_CR43","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"C-K Lee","year":"2003","unstructured":"Lee C-K, Barlogie B, Munshi N et al (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732\u20132739. https:\/\/doi.org\/10.1200\/JCO.2003.01.055","journal-title":"J Clin Oncol"},{"key":"3079_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","volume":"108","author":"JA Zonder","year":"2006","unstructured":"Zonder JA, Barlogie B, Durie BGM et al (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108:403. https:\/\/doi.org\/10.1182\/blood-2006-01-0154","journal-title":"Blood"},{"key":"3079_CR45","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"key":"3079_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bjh.13176","volume":"168","author":"MJ Kovacs","year":"2015","unstructured":"Kovacs MJ, Davies GA, Chapman J-AW et al (2015) Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol 168:511\u2013517. https:\/\/doi.org\/10.1111\/bjh.13176","journal-title":"Br J Haematol"},{"key":"3079_CR47","doi-asserted-by":"publisher","first-page":"2264940","DOI":"10.1080\/09537104.2023.2264940","volume":"34","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Khan D, Rana RH et al (2023) Multiple myeloma and its treatment contribute to increased platelet reactivity. Platelets 34:2264940. https:\/\/doi.org\/10.1080\/09537104.2023.2264940","journal-title":"Platelets"},{"key":"3079_CR48","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/rth2.12411","volume":"4","author":"MW Schoen","year":"2020","unstructured":"Schoen MW, Carson KR, Luo S et al (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 4:1203\u20131210. https:\/\/doi.org\/10.1002\/rth2.12411","journal-title":"Res Pract Thromb Haemost"},{"key":"3079_CR49","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","volume":"29","author":"C Ay","year":"2011","unstructured":"Ay C, Dunkler D, Simanek R et al (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29:2099\u20132103. https:\/\/doi.org\/10.1200\/JCO.2010.32.8294","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03079-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:50:49Z","timestamp":1745038249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3079"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03079-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"13 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}